$CYBN the R&D day event today promises to deliver critical updates on Cybin's research and development efforts, most notably the cutting-edge CYB003 clinical trials, which, if approved, would become the first FDA-approved psychedelic drug for treating major depressive disorder and unlock tremendous growth potential.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.